2027 Urology Coding Updates

Spin to Win A Discount

2027 Urology Coding Updates

Prostate Biopsy Modernization, Genomic Testing and Molecular Surveillance

Speaker
R. Sharma
Date
October 27, 2026
Start Time
1:30 PM ET
Duration
30 Minutes

0.5 AAPC CEU APPROVED

Why This Update Matters

Urology carries one of the larger specialty change sets for 2027, and it arrives on two fronts at once.

The prostate biopsy family is being completely modernized. The new structure distinguishes transrectal from transperineal approach, separates regional sampling from targeted lesion sampling, and introduces reporting for fusion-guided and in-bore MRI or CT guided biopsy, with a new add-on code for additional targeted lesions.

Approach, guidance method, targeting and lesion count all become code-determining elements, which means procedure notes that were sufficient in 2026 may not support the correct code in 2027.

Urologic Diagnostic Updates

At the same time, urologic diagnostics expand substantially.

Prostate cancer risk assessment testing and genomic expression profiling, genitourinary circulating tumor DNA testing, AI-supported bladder cancer pathology analysis, renal disease genetic panels, inherited kidney disorder testing, and kidney transplant rejection and fibrosis assays all gain reporting attention.

Bladder cancer cryotherapy adds a treatment reporting option.

Reporting Considerations

These two halves demand different coding disciplines.

Procedural reporting turns on the operative note; molecular reporting turns on test methodology, analyte, specimen and whether the correct pathway is a Category I code, a Proprietary Laboratory Analyses code or an unlisted procedure, with coverage frequently the harder question.

This Session Will Cover

  • Overview of the 2027 urology procedural and diagnostic changes
  • Complete modernization of the prostate biopsy code family
  • Transrectal versus transperineal approach distinctions
  • Regional sampling versus targeted lesion sampling
  • Fusion-guided and in-bore MRI or CT guided biopsy reporting
  • New add-on reporting for additional targeted lesions
  • Operative-note details required for accurate biopsy code selection
  • Prostate cancer risk assessment and genomic expression profiling
  • Genitourinary circulating tumor DNA testing
  • AI-supported bladder cancer pathology analysis and cryotherapy reporting
  • Renal genetic panels, inherited kidney disorders, and transplant rejection and fibrosis assays
  • Category I, PLA and unlisted pathways, MolDX checkpoints and coverage risk

What This Means for Urology Practices

The 2027 changes require attention to both procedural and diagnostic reporting. For prostate biopsies, approach, guidance method, targeting and lesion count become important code-determining elements.

For molecular and genomic services, accurate reporting depends on the test methodology, analyte, specimen and the appropriate reporting pathway, while coverage remains an important consideration.

Who Should Attend?

✓ Certified professional coders
✓ Specialty coders and coding managers
✓ Medical billers and reimbursement professionals
✓ Urology practices and urologic oncology programs
✓ Molecular and genomic testing laboratories
✓ Physicians and nonphysician practitioners
✓ Clinical documentation improvement professionals
✓ Compliance officers and internal auditors
✓ Practice managers and administrators
✓ Charge-capture and charge-master teams
✓ Prior authorization and coverage review teams
✓ EHR, coding-system and workflow implementation teams
✓ Consultants and provider educators

Prepare for the 2027 Urology Coding Changes

Join R. Sharma for this focused 30-minute session covering the 2027 urology procedural and diagnostic changes, prostate biopsy modernization, genomic and molecular testing, and reporting pathways.

October 27, 2026   |   1:30 PM ET   |   30 Minutes
0.5 AAPC CEU APPROVED

CPT® is a registered trademark of the American Medical Association. This educational program is not affiliated with or endorsed by the AMA. Code assignment does not guarantee coverage or payment. Attendees should review applicable federal, state and payer-specific requirements.

  • Complete modernization of the 2027 prostate biopsy code family
  • Transrectal versus transperineal biopsy approach
  • Regional sampling versus targeted lesion sampling
  • Fusion-guided and in-bore MRI/CT-guided biopsy reporting
  • New reporting for additional targeted lesions
  • Prostate cancer risk assessment and genomic expression profiling
  • Genitourinary circulating tumor DNA testing
  • AI-supported bladder cancer pathology analysis
  • Renal genetic panels and inherited kidney disorder testing
  • Category I, PLA and unlisted reporting pathways and coverage considerations
  • Overview of the 2027 urology coding changes
  • Modernization of the prostate biopsy code family
  • Transrectal and transperineal approach reporting
  • Regional versus targeted lesion sampling
  • Fusion-guided and in-bore MRI/CT-guided biopsy
  • Additional targeted lesion reporting
  • Genomic expression profiling and prostate cancer risk assessment
  • Circulating tumor DNA and molecular testing
  • AI-supported pathology and renal genetic testing
  • Category I, PLA, unlisted codes and coverage considerations
  • Identify the major 2027 coding changes affecting urology services.
  • Understand the revised structure of the prostate biopsy code family.
  • Distinguish transrectal from transperineal biopsy approaches.
  • Differentiate regional sampling from targeted lesion sampling.
  • Recognize the reporting requirements for fusion-guided and in-bore MRI/CT-guided biopsies.
  • Understand how additional targeted lesions are reported.
  • Recognize key reporting considerations for genomic and molecular testing.
  • Understand the role of circulating tumor DNA and AI-supported pathology reporting.
  • Identify appropriate reporting pathways for Category I, PLA and unlisted services.
  • Recognize documentation and coverage considerations that may affect accurate reporting.

Webinars

Duration

Speaker

Register

User

Presenter

R.Sharma

(RN, RM)

R. Sharma, is a seasoned healthcare professional with over 20 years of clinical and operational experience. As a registered nurse and midwife, his deep clinical foundation spans hands-on patient care, health information management, revenue cycle management, and health technology systems. He has held various leadership roles across both outpatient and inpatient settings, and was responsible for managing large-scale operations for one of the top 10 hospital groups in the United States. He brings a unique, frontline-informed perspective to discussions on healthcare delivery, operational efficiency, and technology integration.

×

Unlimited Monthly Webinar Access

What’s Included?

  • Unlimited Monthly Access
  • 200+ Pre-recorded Webinars
  • Unlimited Live Webinars
  • Completion Certificates
  • AAPC CEUs for Selected Webinars
  • Cancel Anytime
  • Simple Monthly Billing
Name

SPIN TO WIN!

  • Try Spin the Wheel to discount coupon for your Webinar.
SPIN & REVEAL MY DISCOUNT